Apremilast,a novel PDE4 inhibitor,inhibits spontaneous production of tumour necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis |
| |
| Authors: | Fiona E McCann Andrew C Palfreeman Melanie Andrews Dany P Perocheau Julia J Inglis Peter Schafer Marc Feldmann Richard O Williams Fionula M Brennan |
| |
| Affiliation: | (1) The Kennedy Institute of Rheumatology, Imperial College London, 65 Aspenlea Road, London, W6 8LH, UK;(2) Institute for Molecular Bioscience, University of Queensland, Bldg 80 Services Road, Brisbane, QLD, 4072, Australia;(3) Pharmacology & Anaesthesiology Unit, School of Medicine & Pharmacology, University of Western Australia, 35 Stirling Highway, Crawley, WA, 6009, Australia;(4) Translational Development, Celgene Corporation, 86 Morris Avenue, Summit, NJ 07901, USA |
| |
| Abstract: | Introduction Type 4 phosphodiesterases (PDE4) play an important role in immune cells through the hydrolysis of the second messenger, cAMP. Inhibition of PDE4 has previously been shown to suppress immune and inflammatory responses, demonstrating PDE4 to be a valid therapeutic target for immune-mediated pathologies. We assessed the anti-inflammatory effects of a novel PDE4 inhibitor, apremilast, in human synovial cells from rheumatoid arthritis (RA) patients, as well as two murine models of arthritis. |
| |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ |
|
